When the orthotopic 4T1 tumors were measurable (20–40 mm3), we started treatment and tumor volume monitoring in different groups that received either (i) vehicle and isotype control, (ii) 30 mg/kg twice per day EVT801, (iii) anti-CTLA-4 twice per week, or (iv) a combination of EVT801 and anti-CTLA-4 (Fig. 6A). The gene discussed is CTLA4; the disease is neoplasm.